TG Therapeutics | TGTX - Interest Expense On Debt


TG Therapeutics reported $7.67M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 657M 4M Mar/2026
Ardelyx USD 5.6M 160K Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Corcept Therapeutics USD 814.88M 809.46M Mar/2026
Curis USD 178K 441K Dec/2023
Gilead Sciences USD 240M 15M Mar/2026
J&J USD 43M 25M Mar/2026
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
Novartis USD 343M 39M Mar/2026
Novavax USD 5.82M 342K Dec/2025
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
TG Therapeutics USD 7.67M 1.13M Mar/2026
Verastem USD 415K 733K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025